Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Moderately to Severely Active Crohns Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT07499232
What this trial is testing

Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Who this might be right for
Crohn Disease
Janssen Research & Development, LLC 530
Testing effectiveness (Phase 2)Study completedNCT02031276
What this trial is testing

Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.

Who this might be right for
Crohn Disease
AbbVie 121
Large-scale testing (Phase 3)Active Not RecruitingNCT05197049
What this trial is testing

Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

Who this might be right for
Crohn Disease
Janssen Research & Development, LLC 350
Large-scale testing (Phase 3)Active Not RecruitingNCT04524611
What this trial is testing

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

Who this might be right for
Crohn's Disease (CD)
AbbVie 527
Large-scale testing (Phase 3)Ended earlyNCT03440372
What this trial is testing

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Who this might be right for
Crohn Disease
Celgene 625
Large-scale testing (Phase 3)Looking for participantsNCT06819878
What this trial is testing

Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Who this might be right for
Moderately to Severely Active Crohns Disease
Hoffmann-La Roche 600
Post-approval studies (Phase 4)Looking for participantsNCT06257706
What this trial is testing

VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Who this might be right for
Moderately to Severely Active Crohn's DiseaseCrohn DiseaseDisease Crohn
Alimentiv Inc. 304
Testing effectiveness (Phase 2)Ended earlyNCT00792740
What this trial is testing

Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease

Who this might be right for
Crohn's Disease
Italfarmaco 51
Large-scale testing (Phase 3)WithdrawnNCT04643483
What this trial is testing

Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease

Who this might be right for
Crohn's Disease
UCB Biopharma SRL
Large-scale testing (Phase 3)Study completedNCT00206674
What this trial is testing

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

Who this might be right for
Crohn Disease
Genzyme, a Sanofi Company 286
Testing effectiveness (Phase 2)Study completedNCT03681067
What this trial is testing

A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease

Who this might be right for
Crohn Disease
University of Birmingham 5
Large-scale testing (Phase 3)Looking for participantsNCT06227910
What this trial is testing

Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

Who this might be right for
Crohn's Disease
Takeda 396
Early research (Phase 1)Ended earlyNCT03169894
What this trial is testing

Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis

Who this might be right for
Crohn DiseaseUlcerative Colitis
Avalo Therapeutics, Inc. 8
Large-scale testing (Phase 3)Study completedNCT03926130
What this trial is testing

Mirikizumab (LY3074828) in Participants With Crohn's Disease

Who this might be right for
Crohn's Disease
Eli Lilly and Company 1,158
Testing effectiveness (Phase 2)Study completedNCT00101946
What this trial is testing

Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease

Who this might be right for
Crohn's Disease
GlaxoSmithKline 17
Large-scale testing (Phase 3)Looking for participantsNCT05837897
What this trial is testing

Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease

Who this might be right for
Crohn's Disease
Takeda 408
Not applicableStudy completedNCT01338740
What this trial is testing

Switching From Adalimumab to Infliximab

Who this might be right for
Crohn's Disease
University Hospital, Ghent 21
Testing effectiveness (Phase 2)Study completedNCT02365649
What this trial is testing

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy

Who this might be right for
Crohn's Disease
AbbVie 220
Testing effectiveness (Phase 2)Study completedNCT05013905
What this trial is testing

A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)

Who this might be right for
Crohn Disease
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 55
Testing effectiveness (Phase 2)Looking for participantsNCT07483099
What this trial is testing

LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

Who this might be right for
Crohn Disease
Eli Lilly and Company 60
Next Page